• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Exploring Results from CAPItello-291 Trial

Opinion
Video

William J. Gradishar, MD, examines the impact of the CAPItello-291 phase III trial on NCCN breast cancer guidelines, comparing the investigated drug to other PI3K pathway inhibitors and discussing its potential to shape future treatment strategies.

  1. In November 2023, capivasertib received FDA approval for use in advanced hormone receptor-positive breast cancer based on the results from the CAPItello-291 phase III trial. How has capivasertib been integrated into the NCCN guidelines for breast cancer?
    1. What are your thoughts on sequencing of capivasertib use in the management of HR+ breast cancer?
  2. How does capivasertib compare to other PI3K pathway inhibitors alpelisib and inavolisib from safety and efficacy standpoints?
Related Videos
Guy Young, MD
Dr Hans Lee
5 experts are featured in this series
2 experts in this video
5 experts are featured in this series
2 experts in this video
Related Content
BMI | Image Credit: Vitalii Vodolazskyi - stock.adobe.com

Higher BMI Linked to Lower Mortality Rate, Fewer Complications in Non-CF Bronchiectasis

July 18th 2025
Article

Being overweight or obese may lower all-cause mortality risks in non–cystic fibrosis (CF) bronchiectasis patients, while being underweight increases health complications.

Read More

managed care cast logo

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

December 23rd 2024
Podcast

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

Listen

DLBCL | Image: Atlas of Haematological Cytology

Lack of CD20 Expression Worsens Outcomes for Bispecifics in R/R DLBCL

July 16th 2025
Article

Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and glofitamab bispecific antibodies for their diffuse large B-cell lymphoma (DLBCL).

Read More

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

December 17th 2024
Podcast

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

Listen

Rise in drug pricing | Image Credit: Alex Puhovoy - stock.adobe.com

Medicare Inflation Rebates Show Limited Impact on Drug Price Trends

July 14th 2025
Article

Medicare inflation rebates fail to curb rising drug prices, highlighting the need for further policy action to control costs.

Read More

health care providers - Kirsten D:peopleimages.com.jpeg

Colorectal Cancer Shared Care Model Gains Support From Clinicians

July 14th 2025
Article

New insights highlight clinician support for shared survivorship care and identify key factors for effective implementation.

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.